⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15925957 | 1.00 | — | — | |
| SCHEMBL14749984 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL30893554 | 0.98 | ALOX5 (0.39) | — | |
| SCHEMBL9492020 | 0.82 | — | — | |
| SCHEMBL17676644 | 0.81 | CDC7 (0.36) | — | |
| SCHEMBL13375672 | 0.79 | — | — | |
| SCHEMBL2034431 | 0.76 | — | — | |
| SCHEMBL1618261 | 0.76 | — | — | |
| SCHEMBL11745624 | 0.76 | — | — | |
| SCHEMBL16216103 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612149-A1 | PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| EP-3999508-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-107216312-B | Compound with mutant IDH inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20230147458-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2023-03-30 | — | — | US | disclosed |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
| WO-2017176960-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2014206349-A1 | OXA-THIA-BICYCLO[3.2.1]OCTANE DERIVATIVE, PREPARATION METHOD, AND USE OF SAME | 四川海思科制药有限公司 (CN) | 2014-12-31 | — | — | WO | disclosed |
| US-20130177531-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-11 | — | — | US | disclosed |
| EP-1457482-B9 | Stable isotope-labeled amino acid, method of integrating the same into target protein, method of NMR structural analysis of protein | JAPAN SCIENCE & TECH AGENCY (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-1457482-B1 | Stable isotope-labeled amino acid, method of integrating the same into target protein, method of NMR structural analysis of protein | JAPAN SCIENCE & TECH AGENCY (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-7022310-B2 | Stable isotope-labeled amino acid and method for incorporating same into target protein | AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20050084452-A1 | Stable isotope-labeled amino acid and method for incorporating same into target protein | JAPANESE SCIENCE AND TECHNOLOGY AGENCY | 2005-04-21 | — | — | US | disclosed |
| EP-1457482-A1 | STABLE ISOTOPE-LABELED AMINO ACID, METHOD OF INTEGRATING THE SAME INTO TARGET PROTEIN, METHOD OF NMR STRUCTURAL ANALYSIS OF PROTEIN AND PROCESS FOR PRODUCING SITE-SELECTIVE STABLE ISOTOPE-LABELED FUMARIC ACID AND TARTARIC ACID | Japan Science and Technology Agency (JP) | 2004-09-15 | — | — | EP | disclosed |